Form 4: Avalo Therapeutics Director Exercises Restricted Stock Units

Director June Sherie Almenoff exercised restricted stock units of Avalo Therapeutics, Inc. on March 28, 2025, converting them into common stock.

Summary

• On March 28, 2025, June Sherie Almenoff, a director of Avalo Therapeutics, Inc., exercised 3,167 restricted stock units (RSUs), converting them into 3,167 shares of common stock.
• The transaction was executed pursuant to Rule 10b5-1(c).
• Following the transaction, Ms. Almenoff directly owns 3,167 shares of common stock and indirectly owns 1,000 shares through Meadowlark Management, LLC.
• Ms. Almenoff disclaims beneficial ownership of the shares held by Meadowlark Management, LLC, except to the extent of her pecuniary interest.
• The RSUs were granted on August 13, 2024, and vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent upon continued service.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The exercise of RSUs by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's exercise of previously granted equity compensation.

Stakeholder Impact

• The transaction has a minor dilutive effect on existing shareholders due to the issuance of new shares upon RSU conversion.

Key Dates

Keywords

Avalo Therapeutics, Director, Restricted Stock Units, Common Stock, Form 4, Beneficial Ownership, AVTX